UK markets open in 5 hours 31 minutes

Thermo Fisher Scientific Inc. (TMO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
516.61-1.22 (-0.24%)
At close: 04:00PM EDT
516.25 -0.36 (-0.07%)
After hours: 05:52PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • A
    Aad
    Solid results of a solid company. As being said this should be trading at 600+
  • M
    Matt
    Strong earnings here . I’m buying
  • A
    Aad
    Buying opportunities
  • K
    Kk
    I believe the reason this went down the other day is the inflation numbers which means the fed will raise interest rates which means a stronger dollar which means overseas profits for thermo or any other multinational will b hurt
  • S
    Simran
    Guys/gals - Looking into this stock - what a performance over the past few years! How is this doing so well - I had always thought that the healthcare industry was legacy, old, too slow, always a hot target for regulations/fines/election hot topic and is under risk from government to be overhauled etc

    Given these risks, how do you all feel about TMO? What is so special/proprietary about TMO that other companies like DHR/Medtronic/ISRG may be and others cant copy?
  • A
    Anonymous
    Not only Thermo Fisher will benefit by selling 5 mill Covid19 test kit, but also will sell more of Thermo Fisher's Applied Biosystems 7500 Fast Dx Real-time PCR which run those test kit up to 26,000 samples a day.
    And very expansive Applied Biosystems 7500 Fast Dx Real-time PCR are very high margin product.

    Thermo Fisher will benefit tremendously and it will offset or overcome the other divisions revenue due to recession. TMO strong buy and 5 Year Target price of $500.00
  • A
    Always Right
    $BNGO conversation
    Great overview on sequencing versus mapping from here:
    https://www.reddit.com/r/BNGO/comments/l49l79/found_this_guy_on_twitter_he_explains_bngo_so/

    "
    First, the Saphyr mapper is not a sequencer, it is, as its name say, a mapper. The difference of a genome sequence and a genome map is that the map aids to decipher the sequence more accurately (for sequence I refer to billions of ATCGATCG…).

    A genome map is created before the sequencing begins and provides confidence in the sequence obtained. Therefore, the Saphyr mapper, does not compete or substitute any sequencing technology (either from $PACB, $ILMN, $TMO, etc.), but rather it is —COMPLEMENTARY— to it.

    For an analogy, think of an any given address. Imagine I live at 14th Main street, Springfield, Massachusetts, USA. And someone asks me where I live, and I simply answer “Springfield”. If the person is local of Massachusetts, will probably assume that I live in Springfield MA.

    However, if I’m asked in a state other than MA, and the person is from a state other than MA, will probably ask “which Springfield”, as there are many cities with this name in all USA; I would have to specify “Springfield, MA.”

    If you are familiar with the locality, you will probably assume its broader location. I use this analogy because almost every city in USA has a “Main” street; a lot of states have a “Springfield” city; but also, Main street in Springfield do exists in countries other than USA.

    Following this analogy, if we asked, “what is your address?” the most common different sequencing technologies will give, with great precision, the following answers: $ILMN — 14th Main. $TMO — 14th Main. $QGEN — 14th Main. $PACB — 14th Main, Springfield.

    None of the above will mention “MA, USA”. Is it possible to locate the accurate address with the first three? NO. Is it possible to locate it with PACB? NOT ENTIRELY.

    In the same analogy, if you asked the Saphyr mapper “what is your address?” the answer will be:

    $BNGO — Near Main, Springfield, MA, USA.

    Would you be able to know the precise address? NO. Therefore, there is no technology that could give a complete and accurate answer, yet.

    10) Then why is Bionano’s such a big deal? Because currently, the most common tools for mapping at hospitals and clinics around the world are FISH (fluorescent in situ hybridization), DNA microarrays (commonly known as CMA), chromosome banding (CB), and Karyotypes;

    11) these techniques have existed for at least 20 years and have been the state of the art, so far. What they all have in common is that they are laborious, time consuming and will answer the following to the question “what is your address?”:

    12)

    Karyotype — USA

    Microarays — Springfield

    FISH — MA

    Cromosome banding — Springfield or MA.

    Why is it that people compare Saphyr to PACB? As you can see, the state of the art for the highest precision was held by PACB, but still it won’t give a fully accurate address.

    13) So, if hospitals and clinics around the world needed to figure out what is wrong with your genes at a large scale with the most accurate map/sequence, the only option was PACB.

    14) The biggest disadvantage, however, is that, from all technologies mentioned, PACB is the most expensive and time consuming, and it needs a special expertise that is difficult to find in sequence analysis, hence not many clinics or hospitals even offer this service.

    15) Why is Bionano’s tech the such a big deal? Because it is only as expensive as any of the other mapping tools, it is high throughput, it covers the entire genome(s) at once, it is automated, and it is way more precise than FISH, CMA, CB, and Karyotypes ALL TOGETHER.

    16) Finally, the Saphyr mapper will inexorably find chromosomal re-arrengements missed by PACB—as we all have seen it in their webinars and scientific papers— because they resemble that Springfield was erroneously located in MA, USA—but is rather located in Chelmford, UK.

    17) Why is such a game changer then? Because, if combined, a Saphyr mapper and a sequencing technology (see above) will never miss a mutation or chromosome rearrangement — for large or small this is.

    18) My forecast for the upcoming years is that there will be a massive adoption of mapping tech at hospitals and clinics around the world in the next 5-10 years, which will substitute entirely FISH, CMA, CB, and Karyotypes.

    19) Maybe, if Bionano’s tech is the only one offering optical imaging, it will dominate the entire industry for years.

    As for $BNGO stock price, I have no idea; I am only a scientist that happens to trade.The stock market behaves in ways unpredictable to me.

    20) The only thing I'm certain is that Bionano’s tech is highly disruptive in its niche. And, if there is one thing I've learned from the Market, is that one thing is the company, another thing is its product/service, and a way different beast is its stock price.

    "
  • D
    Doug
    Have you looked at the storage temp for the 90% effective vaccine? Few hospitals have equipment
  • M
    Michael
    I bought TMO in Dec 1984 for $3.86 a share back when it was Thermo Electron! Great company!
  • A
    Aad
    Thermo Fisher is a giant. Im working at a big pharma company (top 5 worldwide) and TMO is our main supplier. TMO is the Amazon of the Life Science sector.
  • J
    Jacob
    Explain to me like I'm 5 why this is still going down in chunks this large. I expected it to recover back to 521 by now like it usually does
  • P
    Pro Portfolio Manager
    TMO is a fantastic company. I disagree with today’s market reaction. The Pfizer news will have a limited effect (if not no effects at all) on TMO and other competitors. Also testing regarding Covid (but also other diseases) will remain very important, as it is the case for instance in Europe and everywhere I go. France just voted another law to extent the period through July 2022 in order to be able to move, go the restaurant etc. with the mandatory testing or « Pass ». Many Europeans countries don’t even have a Pass and testing has to be done even with vaccinated people (which makes sense). Do not follow the crowd and the weak hands.
  • A
    Aad
    ARK bought today. Guess I’m not the only one who wants to have the Amazon of Life Sciences in the portfolio
  • S
    Seth
    Thermo Fisher is raising its 2021 revenue and earnings guidance. The company is raising its revenue guidance by $1.2 billion to $37.1 billion; this would result in 15% revenue growth over 2020. The company is raising its adjusted EPS guidance by $1.30 to $23.37, which would represent 20% growth year over year.
  • B
    Bobby
    TMO is trading at aprox. 20% below fair value with earnings growth of about 73% last year! Solid company. Great financials. Incredible growth.
  • m
    mitchell n
    $ENZ conversation
    From my last month post
    mitchell last month
    $ENZ conversation
    To determine the value of $ENZ we have to look at what the potential is under new management. The assets that Enzo Biochem have such as the FDA approved testing, the platform, & the patents have exponential potential. When I think of a company like Thermo Fisher Scientific Inc. $TMO and how the Enzo assets would be valued as part of their company I go back to previous buyouts that $TMO have made specifically Affymetrix when $TMO paid $1.7 billion, 52% premium from it's closing price of that day all cash after a bidding war ensued. Affymetrix had about $350 million in annual revenue. Given similar valuations that gives me $ENZ a $14 a share valuation on a buy out and that doesn't take into consideration that because of the pandemic $ENZ has become exponentially valuable.
    Less
  • M
    Michael
    I bought TMO 36 years ago (back then it was Thermo Electron) for $4.58 a share. Thru the 1990's, the stock had three 3 for 2 stock splits. I never had a thought about selling any of my TMO holdings. My original reason was simple: demographics (Americans were aging which requires more medical attention). Due to tax consequences, This stock will be part of my estate when I pass. My advise: Choose wisely and stay long. :))
  • B
    BHVR
    Earnings beat estimates

    58.2% jump in quarterly profit on Wednesday, boosted by strength in its life sciences unit which makes raw materials for COVID-19 vaccines as well as robust sales of its analytical instruments.
    The company's net income rose to $1.83 billion, or $4.61 per share, for the second quarter ended July 3, from $1.16 billion, or $2.90 per share, a year earlier.
  • a
    anne
    Thermo is great Lab solution provider, not a Bio tech , a really very strong well run solid company, Im very happy to load up at these levels, ..! bargain